Unlike other available blood and urine tests, the miR Sentinel Prostate Cancer Test characterizes the entire prostate, allowing for more accurate results. If molecular evidence of aggressive prostate cancer is present, the results classify a patient’s condition into categories describing the risk classification of the tumor.
The prostate naturally releases molecules into urine, including several different kinds of genetic material that vary depending on the presence and severity of prostate cancer. We extract and measure these fragments, known as small non-coding RNAs, using gene expression technology and a proprietary algorithm. The miR Sentinel Prostate Cancer Test is a standalone test – it does not rely on PSA or biopsy material.
This result indicates that the patient finding shows No Molecular Evidence of Prostate Cancer.
This result indicates that the patient presents Molecular Evidence of Low-Risk Prostate Cancer, which is consistent with the NCCN Very Low and Low Risk Groups
This result indicates that the patient presents Molecular Evidence of Moderate-Risk Prostate Cancer, which is consistent with the NCCN Favorable Intermediate Risk Group
This result indicates that the patient presents Molecular Evidence of Elevated-Risk Prostate Cancer, which is consistent with the NCCN Unfavorable Intermediate, High, and Very High Risk Groups
miR Scientific’s unique sncRNA extraction and interrogation techniques coupled with an advanced proprietary algorithm will allow physicians to confidently detect and classify prostate cancers with just one urine sample, reducing unnecessary prostate cancer diagnostic procedures and treatments.
Book an appointment with your medical provider and request a prescription for the miR Sentinel Prostate Cancer Test™.
Provide a simple urine sample
in your provider’s office
Your provider will receive comprehensive and accurate results--together you will discuss their meaning and next steps.
The report will be securely delivered to the provider who ordered the test, either via secure fax or email.
The miR Sentinel™ Prostate Cancer Test is commercially available in most US states as well as Puerto Rico. The Test is not currently available in New York, California, Pennsylvania, Maryland and Washington, D.C. We are working to bring miR Sentinel™ to all 50 U.S. states, all territories and global markets including Canada, Israel and Singapore.
miR Scientific Collection Kits can be ordered by a healthcare provider over the phone, by contacting miR Scientific’s customer service team at 1-855-55CALLMIR.
miR Scientific is currently exploring insurance coverage and Medicare reimbursement with several carriers in the US and Puerto Rico but is currently an out-of-network provider. Patients will have the option of paying with credit card or we can assist with submitting out-of-network claims to their carrier. We do offer a patient assistance program called miR Access™ to support access to the test for those in need here: https://www.mirsentinel.com/insurance-billing
miR's Sentinel™ Prostate Cancer Test is currently only available through a health care provider. Please speak with your physician about possible testing options.
We're here to help! Visit our support center for FAQs and options to connect with a miR Sentinel expert directly.SUPPORT CENTER